Budget 2025: 36 life-saving drugs fully exempted from custom duty – Check full list

Budget 2025: In July last year, after the Lok Sabha elections, the Health Ministry was allocated Rs 90958.63 crore in the Union Budget 2024-25.

Budget2025,Nirmala Sitharaman,Objectives Of Budget,36 Life-Saving Drugs,Basic Customs Duty, healthcare news, budget 2025 news,
Budget 2025: The Finance Minister also informed that the government will exempt basic custom duty on 37 more medicines. (Image Credits: FE)

Budget 2025: Finance Minister Nirmala Sitharaman on Saturday announced that 36 life-saving drugs would be exempted from basic customs duty. During her budget 2025 speech, these drugs include essential medicines used to treat cancer and other rare diseases.

The Finance Minister also informed that the government will exempt basic custom duty on 37 more medicines.The Finance Minister also announced the launch of 200 cancer daycare centres will be set up in government hospitals within 3 years in all districts.

“To provide relief to patients, particularly those suffering from cancer, rare diseases and other severe chronic diseases, I propose to add 36 lifesaving drugs and medicines to the list of medicines fully exempted from Basic Customs Duty (BCD). I also propose to add 6 lifesaving medicines to the list attracting concessional customs duty of 5 percent. Full exemption and concessional duty will also respectively apply on the bulk drugs for manufacture of the above,” the Finance Minister.

Here is the list of 36 life-saving medicines that has exempted from the custom duty:

S. No.Drug Name
1Onasemnogene abeparvovec
2Asciminib
3Mepolizumab
4Pegylated Liposomal Irinotecan
5Daratumumab
6Daratumumab subcutaneous
7Teclistamab
8Amivantamab
9Alectinib
10Risdiplam
11Obinutuzumab
12Polatuzumab vedotin
13Entrectinib
14Atezolizumab
15Spesolimab
16Velaglucerase Alpha
17Agalsidase Alfa
18Rurioctocog Alpha Pegol
19Idursulphatase
20Alglucosidase Alfa
21Laronidase
22Olipudase Alfa
23Tepotinib
24Avelumab
25Emicizumab
26Belumosudil
27Miglustat
28Velmanase Alfa
29Alirocumab
30Evolocumab
31Cystamine Bitartrate
32CI-Inhibitor injection
33Inclisiran
34Agalsidase Beta
35Imiglucerase
36Eptacog alfa activated recombinant coagulation factor VIIa

She also said that specified drugs and medicines under Patient Assistance Programmes run by pharmaceutical companies are fully exempt from BCD, provided the medicines are supplied free of cost to patients. “I propose to add 37 more medicines along with 13 new patient assistance programmes,” she said.

In July last year, after the Lok Sabha elections, the Health Ministry was allocated Rs 90958.63 crore in the Union Budget 2024-25. The Ministry has witnessed a hike of 12.9 per cent over 80,517.62 crore in the Budget (revised estimates) for 2023-2024.

Here is the list of 37 more life- saving medicines along with 30 new patient assistance programmes that has exempted from the custom duty:

S.NoDrug NamePatient Assistance Program (PAP)Company Name
1Pembrolizumab KeyPAP 1.0MSD Pharmaceuticals
2Pembrolizumab KIRANMSD Pharmaceuticals
3LorlatinibLorbriquaCarePfizer Products India Pvt. Ltd.
4DacomitinibDacoCarePfizer Products India Pvt. Ltd.
5Inotuzumab OzogamicinHemaCarePfizer Products India Pvt. Ltd.
6RibociclibUMAANGNovartis Healthcare Pvt. Ltd.
7DabrafenibUMAANGNovartis Healthcare Pvt. Ltd.
8SelumetinibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
9BenralizumabAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
10FulvestrantAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
11AcalabrutinibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
12OlaparibAstraZeneca Pharma PAPAstraZeneca Pharma India Ltd.
13AmivantamabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
14TeclistamabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
15UstekinumabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
16Daratumumab + Hyaluronidase-fihjJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
17IbrutinibJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
18BortezomibJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
19DaratumumabJohnson and Johnson PAPJohnson & Johnson Pvt. Ltd.
20CetuximabRainbow PAPMerck Specialties Pvt. Ltd.
21AvelumabMy Bavencio Assist ProgramMerck Specialties Pvt. Ltd.
22TepotinibMy Tepmetko Patient Access ProgramMerck Specialties Pvt. Ltd.
23Brentuximab VedotinTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
24VedolizumabTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
25Velaglucerase AlphaTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
26Agalsidase AlphaTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
27IdursulphaseTakeda PAPTakeda Biopharmaceuticals India Pvt. Ltd.
28MepolizumabGSK Pharmaceuticals Ltd.
29AlectinibThe Blue TreeRoche Products India Pvt. Ltd.
30Risdiplam PowderThe Blue TreeRoche Products India Pvt. Ltd.
31EmicizumabThe Blue TreeRoche Products India Pvt. Ltd.
32AtezolizumabThe Blue TreeRoche Products India Pvt. Ltd.
33Pertuzumab + TrastuzumabThe Blue TreeRoche Products India Pvt. Ltd.
34OcrelizumabThe Blue TreeRoche Products India Pvt. Ltd.
35Polatuzumab VedotinThe Blue TreeRoche Products India Pvt. Ltd.
36FaricimabThe Blue TreeRoche Products India Pvt. Ltd.
37LuspaterceptBristol-Myers Patient Assistance ProgramBristol-Myers Squibb India Pvt. Ltd.

“This notification shall come into force on the 2nd day of February, 2025,” the Finance Ministry stated.

During her Budget 2024 speech, Sitharaman proposed that three cancer treatment medicines be exempted from basic customs duty completely to help patients with cancer. She also proposed changes in the basic customs duty for X-ray tubes and Flat panel detectors for use in medical X-ray machines “under the phased manufacturing programme to synchronise them to domestic capacity addition.”

Get live Share Market updates, Stock Market Quotes, and the latest India News
This article was first uploaded on February one, twenty twenty-five, at zero minutes past one in the afternoon.
X